Aptevo Therapeutics (NASDAQ:APVO) Upgraded at Wall Street Zen

Aptevo Therapeutics (NASDAQ:APVO) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Sunday.

Separately, Weiss Ratings restated a “sell (e)” rating on shares of Aptevo Therapeutics in a report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Aptevo Therapeutics presently has a consensus rating of “Hold”.

Aptevo Therapeutics Trading Down 5.3%

Shares of NASDAQ APVO opened at $4.27 on Friday. The stock’s 50-day moving average is $6.53 and its 200 day moving average is $16.94. The stock has a market cap of $4.27 million, a price-to-earnings ratio of 0.00 and a beta of 1.44. Aptevo Therapeutics has a 1-year low of $3.95 and a 1-year high of $1,299.60.

Aptevo Therapeutics (NASDAQ:APVO) last issued its earnings results on Friday, March 27th. The biotechnology company reported $118.23 earnings per share (EPS) for the quarter, topping the consensus estimate of ($8.10) by $126.33. On average, analysts forecast that Aptevo Therapeutics will post -15.84 EPS for the current fiscal year.

Institutional Trading of Aptevo Therapeutics

A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Virtu Financial LLC purchased a new position in Aptevo Therapeutics Inc. (NASDAQ:APVO) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 38,282 shares of the biotechnology company’s stock, valued at approximately $56,000. Virtu Financial LLC owned approximately 1.16% of Aptevo Therapeutics at the end of the most recent reporting period. 8.06% of the stock is currently owned by institutional investors and hedge funds.

About Aptevo Therapeutics

Aptevo Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, focused on the discovery and development of novel immunotherapies for oncology and autoimmune diseases. Founded in 2012 as a spin-off from Emergent BioSolutions, the company builds on expertise in protein engineering and translational research to create targeted biologics that engage the body’s immune system.

The company’s core technologies include the ADAPTIR platform, which enables the design of bispecific and multispecific protein scaffolds with customizable binding domains, and the KNOCKOUT platform, which incorporates non-natural amino acids to enhance therapeutic properties such as stability and half-life.